Nasdaq · CIK 0000939767 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exelixis Inc
EXEL chart by TradingView
PRICE HISTORY
LIVE · NASDAQEXEL chart by TradingView
- REVENUE FY2025 ENDED JAN 2026
- $2.3B
- EBITDA
- $0.9B
- FREE CASH FLOW
- $0.9B
- EPS
- $2.78
- GROSS MARGIN
- 96.39%
- ROIC
- —
Q2 FY26ENDED JUL 2026HOVERDRAG ACROSS ANY CHART TO SCRUB ALL 24 · 40 QUARTERS SHOWNVALUATIONGROWTHPROFITABILITY & RETURNSCASH & CAPITALBALANCE SHEET
VALUATION
what you pay for a unit of the business7 CHARTS⤢
P / E RATIO (TTM)
16.9x
-99%8.8x1176.6x
⤢
P / SALES (TTM)
6.0x
-78%3.1x26.5x
⤢
P / BOOK
7.9x
-92%2.0x102.4x
⤢
EV / EBITDA (TTM)
—
-52%75.8x157.1x
⤢
EV / REVENUE (TTM)
—
-19%20.2x27.1x
⤢
FCF YIELD (TTM)
8.08%
+5.4pp1.53%9.58%
⤢
DIVIDEND YIELD (TTM)
—
GROWTH
is the business getting bigger5 CHARTS⤢
REVENUE
$0.6B
+911%⤢
EBITDA (DERIVED)
$0.3B
+3277%⤢
NET INCOME
$0.2B
+$0.2B⤢
EPS (DILUTED)
$0.82
+$0.86⤢
REVENUE GROWTH YOY
10.63%
-520.5pp-14.95%680.65%
PROFITABILITY & RETURNS
what survives to the bottom, and what it earns on capital4 CHARTS⤢
FCF MARGIN
47.87%
+57.2pp-9.35%103.65%
⤢
RETURN ON CAPITAL
—
+242.7pp-128.08%114.66%
⤢
RETURN ON EQUITY (TTM)
46.68%
+493.3pp-446.61%58.03%
MARGIN FUNNEL
every line is a share of the same revenue, so they read on one scale — the gaps are what each layer takes out, and net rises above operating when income arrives from outside the businessGROSS MARGIN96.71%
OPERATING MARGIN39.51%
NET MARGIN33.73%
FCF MARGIN47.87%
CASH & CAPITAL
where the money actually goes5 CHARTS⤢
FREE CASH FLOW
$0.3B
+$0.3B⤢
STOCK-BASED COMP
$0.0B
+804%⤢
CAPITAL EXPENDITURE
$0.0B
+20555%⤢
SHARES OUTSTANDING
0.26B
+1%⤢
DIVIDEND / SHARE
—
BALANCE SHEET
how much cushion there is3 CHARTS⤢
CASH & EQUIVALENTS
$0.3B
+153%⤢
TOTAL DEBT
—
-41%⤢
DEBT / EBITDA (TTM)
—
-52%1.3x2.7x
OWNERSHIP
10 LARGEST HOLDERS · WHO OWNS THE FLOATINSTITUTIONS 107.47%INSIDERS 1.85%OTHER / RETAIL 0.00%960 INSTITUTIONAL FILERS
| HOLDER | % HELD | SHARES | VALUE | CHANGE |
|---|---|---|---|---|
| Blackrock Inc. | 12.26% | 30.8M | $1.67B | +2.0% |
| Renaissance Technologies, LLC | 5.46% | 13.7M | $742.2M | -1.3% |
| Farallon Capital Management LLC | 5.22% | 13.1M | $708.9M | NEW |
| AQR Capital Management, LLC | 5.21% | 13.1M | $708.1M | -4.1% |
| Vanguard Portfolio Management LLC | 4.81% | 12.1M | $653.5M | NEW |
| Vanguard Capital Management LLC | 4.48% | 11.3M | $608.8M | NEW |
| State Street Corporation | 4.10% | 10.3M | $556.8M | -1.8% |
| Fuller & Thaler Asset Management Inc. | 3.40% | 8.5M | $461.9M | +7.3% |
| LSV Asset Management | 3.24% | 8.1M | $440.5M | +5.2% |
| Geode Capital Management, LLC | 3.10% | 7.8M | $421.5M | +3.5% |
AS OF 2026-03-31 · MOST RECENT 13F FILINGS
SOURCE → 10-K · 10-Q · 8-K / GUIDANCE · ALL FILINGS
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.